Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
NCT04201756
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
47
Enrollment
OTHER
Sponsor class
Conditions
Lung Adenocarcinoma Stage III
EGFR Gene Mutation
Interventions
DRUG:
Afatinib
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China